Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEONID SHUNYAKOV

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1396709895
CMS profile
335741
Location
BOLIVAR, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$348,699.85

445 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $50,234.15 53
Janssen Biotech, Inc. $38,301.85 37
Seagen Inc. $36,516.31 27
Regeneron Healthcare Solutions, Inc. $30,117.55 19
AbbVie Inc. $24,221.60 31
Ipsen Biopharmaceuticals, Inc $23,055.30 9
E.R. Squibb & Sons, L.L.C. $19,952.35 17
Genentech USA, Inc. $17,926.44 22
Daiichi Sankyo Inc. $15,500.13 14
Mirati Therapeutics, Inc. $13,635.34 13
JAZZ PHARMACEUTICALS INC. $10,972.70 7
Karyopharm Therapeutics Inc. $9,997.61 6
Gilead Sciences, Inc. $9,095.20 23
BeiGene USA, Inc. $8,647.91 13
Novocure Inc. $6,169.16 13
Incyte Corporation $4,358.49 4
Eisai Inc. $4,198.53 7
Astellas Pharma US Inc $3,925.67 8
EMD Serono, Inc. $3,250.95 6
Janssen Scientific Affairs, LLC $2,955.59 6
Johnson & Johnson Health Care Systems Inc. $2,940.00 1
G1 Therapeutics, Inc. $2,800.00 1
GlaxoSmithKline, LLC. $2,036.82 3
NOVARTIS PHARMACEUTICALS CORPORATION $1,909.92 23
GENZYME CORPORATION $1,429.84 3
PFIZER INC. $1,130.61 6
Amgen Inc. $893.13 2
Exelixis Inc. $886.67 4
Celgene Corporation $681.98 30
Lilly USA, LLC $195.96 2
Pharmacyclics LLC, An AbbVie Company $149.09 7
Adaptive Biotechnologies Corporation $114.57 1
Rigel Pharmaceuticals, Inc. $92.88 6
Takeda Pharmaceuticals U.S.A., Inc. $74.22 2
Bayer Healthcare Pharmaceuticals Inc. $65.14 3
PharmaEssentia USA Corporation $37.35 2
Foundation Medicine, Inc. $34.65 2
Kite Pharma, Inc. $33.88 2
Boehringer Ingelheim Pharmaceuticals, Inc. $23.53 1
SERVIER PHARMACEUTICALS LLC $21.47 1
Organon LLC $20.06 1
MENARINI SILICON BIOSYSTEMS, INC. $18.54 1
Mylan Institutional Inc. $16.93 1
ACCORD HEALTHCARE, INC. $15.69 1
Kyowa Kirin, Inc. $15.02 1
Alnylam Pharmaceuticals Inc. $13.51 1
Apellis Pharmaceuticals, Inc. $13.31 1
ARRAY BIOPHARMA INC $2.25 1

Page 2 of 9; records 51–100 of 445 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEONID SHUNYAKOV

NPI 1396709895 · CMS profile ID 335741

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BOLIVAR, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 9; records 51–100 of 445 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396709895?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEONID SHUNYAKOV, NPI 1396709895, CMS profile ID 335741. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 445 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396709895?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LEONID SHUNYAKOV, NPI 1396709895, CMS profile ID 335741. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 445 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396709895?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LEONID SHUNYAKOV, NPI 1396709895, CMS profile ID 335741, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 9; records 51–100 of 445 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1396709895?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

445 matching records · $348,699.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 445 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 445.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $237.3811/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006586245 CMS
Janssen Biotech, Inc. $119.7911/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988298005 CMS
AbbVie Inc. $114.6311/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998994737 CMS
AbbVie Inc. $201.7411/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998994739 CMS
BeiGene USA, Inc. $16.2511/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051187105 CMS
AstraZeneca Pharmaceuticals LP $207.6211/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012054411 CMS
AstraZeneca Pharmaceuticals LP $36.9711/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014819173 CMS
AstraZeneca Pharmaceuticals LP $10.8211/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014875709 CMS
AstraZeneca Pharmaceuticals LP $32.5211/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015838645 CMS
Janssen Biotech, Inc. $12.8011/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988297925 CMS
JAZZ PHARMACEUTICALS INC. $127.7111/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058418493 CMS
Celgene Corporation $19.0211/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015377001 CMS
Gilead Sciences, Inc. $662.8011/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025494301 CMS
AstraZeneca Pharmaceuticals LP $1,387.5011/07/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014989041 CMS
Genentech USA, Inc. $15.4411/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040436281 CMS
Astellas Pharma US Inc $0.7711/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034645085 CMS
Janssen Scientific Affairs, LLC $15.3011/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988524029 CMS
Janssen Scientific Affairs, LLC $91.7811/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988524035 CMS
Astellas Pharma US Inc $16.2211/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034641599 CMS
MENARINI SILICON BIOSYSTEMS, INC. $18.5411/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060195593 CMS
Rigel Pharmaceuticals, Inc. $20.4411/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033432069 CMS
Daiichi Sankyo Inc. $832.5011/01/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006612823 CMS
Novartis Pharmaceuticals Corporation $10.3611/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993322883 CMS
AbbVie Inc. $4,725.0010/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998994731 CMS
Janssen Biotech, Inc. $1,100.0010/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988297995 CMS
Regeneron Healthcare Solutions, Inc. $21.2810/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999441891 CMS
E.R. Squibb & Sons, L.L.C. $11.4910/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015376931 CMS
AbbVie Inc. $126.4810/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998994725 CMS
AbbVie Inc. $8.4510/26/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998994729 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.0510/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000695477 CMS
Celgene Corporation $11.4510/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015377489 CMS
Ipsen Biopharmaceuticals, Inc $6,090.0010/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045446337 CMS
Ipsen Biopharmaceuticals, Inc $97.4010/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045446347 CMS
Genentech USA, Inc. $501.7310/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040436373 CMS
Genentech USA, Inc. $4,040.0010/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040436377 CMS
Genentech USA, Inc. $128.8610/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040436385 CMS
GlaxoSmithKline, LLC. $19.7310/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003156257 CMS
Pharmacyclics LLC, An AbbVie Company $14.6410/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998295653 CMS
Novocure Inc. $71.2310/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021076051 CMS
Novartis Pharmaceuticals Corporation $17.9910/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993322885 CMS
Novocure Inc. $158.4610/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021076059 CMS
Ipsen Biopharmaceuticals, Inc $6,960.0010/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045446335 CMS
Ipsen Biopharmaceuticals, Inc $115.6710/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045446351 CMS
Janssen Biotech, Inc. $14.0410/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988298025 CMS
Genentech USA, Inc. $4,040.0010/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040436353 CMS
Genentech USA, Inc. $372.0410/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040436361 CMS
Genentech USA, Inc. $150.0010/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040436365 CMS
Daiichi Sankyo Inc. $16.8710/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006496091 CMS
Gilead Sciences, Inc. $12.8610/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026048601 CMS
SERVIER PHARMACEUTICALS LLC $21.4710/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055090411 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $324,796.96 410
PY2020 $129,096.10 205
PY2021 $233,777.75 277
PY2022 $334,003.60 455
PY2023 $348,699.85 445
PY2024 $327,068.46 442
PY2025 $389,146.89 417

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $12,457.56 11
PY2024 Principal investigator $113,549.17 30
PY2023 Recipient $1,734.05 1
PY2023 Principal investigator $159,918.88 34
PY2022 Principal investigator $155,538.67 49
PY2021 Recipient $815.45 1
PY2021 Principal investigator $143,240.51 97
PY2020 Principal investigator $57,996.88 32
PY2019 Recipient $961.88 1
PY2019 Principal investigator $85,571.90 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $196.00 11/07/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737881
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $353.60 11/07/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737883
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,035.00 11/07/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,040.20 09/18/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) No dispute reported 06/30/2026 1223285688
Principal investigator 1 Mirati Therapeutics, Inc. $5,246.16 07/08/2025 Non-covered Recipient Entity
Central Care Cancer Center
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236531197
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $925.00 04/28/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737875
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $822.00 04/28/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737877
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $104.00 04/28/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737879
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $249.60 01/23/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737871
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $156.00 01/07/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737873
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $330.00 01/03/2025 Non-covered Recipient Entity
Central Care Cancer Center
A Phase 3b randomized study of lenalidomide (CC-5013)plus rituximab maintenance therapy followed by lenalidomide singe-agent maintenance vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma No dispute reported 06/30/2026 1235998214